Gilead Sciences Stock Crashes 9% After Cancer Drug Fails A Key Test

Gilead Sciences announced that its drug, Trodelvy, did not meet the success criteria in a Phase 3 study for patients with non-small cell lung cancer. The study aimed to improve overall survival for patients with advanced or metastatic lung cancer. One group of patients, who did not respond to previous treatment with an immuno-oncology drug, showed a three-month improvement in overall survival. Gilead plans to explore further development of Trodelvy for these patients. However, Gilead’s stock fell 8.7% in premarket trading.